Journal
FUTURE ONCOLOGY
Volume 12, Issue 18, Pages 2095-2105Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2016-0118
Keywords
basal cell carcinoma; BOLT trial; sonidegib
Categories
Ask authors/readers for more resources
The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by the US FDA for the treatment of patients with locally advanced basal cell carcinoma. This article will provide an overview of the pharmacology and pharmacokinetics of sonidegib and in-depth analysis of the BOLT trial with additional data from the 12-month update. The present challenges associated with Hedgehog inhibitors will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available